2 - TI Pharma

More documents

Recommendations

Info

Chapter 2 Novel Insights into Glucocorticoid-Mediated Diabetogenic Effects: Towards Expansion of Therapeutic Options? D.H. van Raalte, D.M. Ouwens and M.Diamant European Journal of Clinical Investigation. 2009; 39(2):81-93
Page 2: Diabetogenic Effects of Glucocortic
Page 6: VRIjE UNIVERSITEIT Diabetogenic Eff
Page 10: Leescommissie: prof.dr. M. Boers pr
Page 14: Chapter 12 Angiopoietine-like prote
Page 22: Chapter 1 General Introduction and
Page 26: Figure 1. Overview of the therapeut
Page 30: inding to the intracellular GR, fol
Page 34: further explored the effects of bot
Page 38: 17. Kaplan SA, Shimizu CS. Effects
Page 48: Chapter 2 Glucocorticoids: metaboli
Page 92:
Chapter 2 Glucocorticoids: metaboli
Page 96:
Page 100:
Page 110:
Chapter 3 Prednisolone-Induced Beta
Page 114:
INTRoDUCTIoN Glucocorticoids (GCs),
Page 118:
content was measured in acid-ethano
Page 122:
Figure 2. Effects of prednisolone o
Page 126:
Figure 5. Effects of prednisolone a
Page 130:
Prednisolone increases expression o
Page 134:
activity of protein phosphatase(s)
Page 138:
REFERENCES 1. Clore jN, Thurby-Hay
Page 142:
29. Shimizu N, Yoshikawa N, Ito N,
Page 150:
Chapter 4 Acute and 2-Week Exposure
Page 154:
Glucocorticoids (GCs), such as pred
Page 158:
meal beginning immediately after th
Page 162:
Table 1 (Acute study). Subject char
Page 166:
Figure 3. A two-week treatment with
Page 170:
prednisolone, as the most widely pr
Page 174:
REFERENCES 1. Schacke H, Docke WD,
Page 182:
Chapter 5 Islet-cell Dysfunction In
Page 186:
Glucocorticoids (GCs) are the corne
Page 190:
Hyperinsulinemic-euglycemic clamp a
Page 194:
called the potentiation factor rati
Page 198:
iAUC: β=0.126; P=0.638; R 2 =0.119
Page 202:
Figure 3. Postprandial responses at
Page 206:
Safety and tolerability: One subjec
Page 210:
towards withdrawal of vagal activit
Page 214:
Page 218:
29. Hamamdzic D, Duzic E, Sherlock
Page 222:
Supplementary Figure 3. Patient flo
Page 230:
Chapter 6 Glucocorticoid Receptor G
Page 234:
Excess glucocorticoid (GC) levels i
Page 238:
Figure 1. Schematic overview of the
Page 242:
N363S (rs6195) AA 222 766 (722-812)
Page 246:
possibility to have missed subtle e
Page 250:
14. Russcher H, Smit P, van den Akk
Page 254:
SUPPLEMENTAL FILES Supplementary Fi
Page 258:
Supplemental Table 2. Major inclusi
Page 262:
Haplotype 5 0 223 767 (724-813) 248
Page 268:
Chapter 7 GLP-1 prevents glucocorti
Page 272:
Page 276:
Page 280:
Page 284:
Page 288:
Page 292:
Page 298:
PART Mechanisms of glucocorticoid-i
Page 304:
Chapter 8 Glucocorticoids affect in
Page 308:
Page 312:
Page 316:
Page 320:
Page 324:
Page 328:
Page 332:
Page 336:
Page 340:
Page 344:
Page 350:
Chapter 9 Glycosphingolipid Metabol
Page 354:
INTRoDUCTIoN Glucocorticoids (GCs)
Page 358:
Experimental protocol: The design o
Page 362:
oxidative phosphorylation (OXPHOS)
Page 366:
Table 3. Mitochondrial respiration
Page 370:
prednisolone 30 mg group, and the c
Page 374:
Page 378:
29. Kabayama K, Sato T, Saito K, Lo
Page 386:
Chapter 10 Glucocorticoid Treatment
Page 390:
Glucocorticoids (GCs) represent the
Page 394:
capillary recruitment. Capillary re
Page 398:
elatively small numbers in each gro
Page 402:
Table 2. Metabolic parameters and b
Page 406:
Table 3. Capillary density before a
Page 410:
Prednisolone and insulin signaling
Page 414:
DISCUSSIoN This is the first study
Page 418:
glucose uptake suggesting that the
Page 422:
15. de jongh RT, Serne EH, RG Ij, d
Page 426:
SUPPLEMENTARy MATERIAL Supplemental
Page 434:
Chapter 11 Glucocorticoids alter Su
Page 438:
Glucocorticoids (GCs) are important
Page 442:
Adipose tissue was washed with ster
Page 446:
Figure 1. Effects of glucocorticoid
Page 450:
Impaired insulin action in adipose
Page 454:
REFERENCES 1. van Raalte DH, Ouwens
Page 458:
30. Ouchi N, Parker JL, Lugus JJ, W
Page 464:
Chapter 12 Angptl4 in glucocorticoi
Page 468:
Page 472:
Page 476:
Page 480:
Page 484:
Page 488:
Page 494:
PART Metabolic Effects of Glucocort
Page 500:
Chapter 13 Glucocorticoids in acute
Page 504:
Page 508:
Page 512:
Page 516:
Page 520:
Page 524:
Page 528:
Page 534:
Chapter 14 Glucose Tolerance, Insul
Page 538:
INTRoDUCTIoN Rheumatoid arthritis (
Page 542:
independent ethics committee approv
Page 546:
Glucose tolerance state: The preval
Page 550:
Data represent means ± standard de
Page 554:
**** Number of DMARDs (both synthet
Page 558:
Effect modification: As compared to
Page 562:
described here, may even be underes
Page 566:
15. Wolfe F, Michaud K. Corticoster
Page 574:
PART Discussion V
Page 580:
Chapter 15 General Discussion Gluco
Page 584:
Chapter 15 General Discussion Studi
Page 588:
Chapter 15 General Discussion Figur
Page 592:
Chapter 15 General Discussion AMP-a
Page 596:
Chapter 15 General Discussion shown
Page 600:
Chapter 15 General Discussion decre
Page 604:
Chapter 15 General Discussion Inter
Page 608:
Chapter 15 General Discussion Mecha
Page 612:
Chapter 15 General Discussion and a
Page 616:
Chapter 15 General Discussion and p
Page 620:
Chapter 15 General Discussion short
Page 624:
Chapter 15 General Discussion Table
Page 628:
Chapter 15 General Discussion REFER
Page 632:
Chapter 15 General Discussion 30. S
Page 636:
Chapter 15 General Discussion 58. L
Page 640:
Chapter 15 General Discussion 88. F
Page 644:
Chapter 15 General Discussion 119.
Page 648:
Page 652:
Page 658:
Nederlandse Samenvatting Diabetogen
Page 662:
het bleek ook heel effectief bij de
Page 666:
door prednisolon behandeling. In di
Page 670:
In deel 4 van mijn proefschrift bes
Page 678:
Dankwoord Acknowledgements
Page 682:
Geachte Dr. Ouwens, beste Margriet.
Page 686:
Dr. Kersten, beste Sander, veel dan
Page 694:
Biography
Page 698:
Daniël Henri van Raalte was born o
Page 704:
List of Publications 1. van Genugte
Page 708:
List of Publications 20. van Raalte
Page 716:
List of co-author affiliations Andr
Page 720:
List of co-author affiliations Jos
Page 724:
List of co-author affiliations Timo
Page 732:
Color Figures Chapter 1 Figure 1. O
show all

2 - TI Pharma

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?